Latest:
Perspectives on Treating CCA Moving Forward
A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine
Latest:
New Study Shows Lung Cancer Surveillance in the United States Misses Most Patients; Northwestern Medicine Researchers Urge Universal Age-Based Screening
Northwestern Medicine researchers discovered only 35% of patients would have qualified for lung cancer screening according to the U.S. Preventive Services Task Force (USPSTF) criteria.
Casey Degen, MD
Latest:
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, is a clinical associate professor in the Department of Clinical Oncology and the deputy medical director of the Phase 1 Clinical Trials Centre at The Chinese University of Hong Kong; as well as an honorary consultant in the Department of Clinical Oncology at the Prince of Wales Hospital/New Territories East Cluster, Hospital Authority
Latest:
Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC
Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.
Lucio N. Gordan, MD
Latest:
Key Takeaways and Future Perspectives for In-House Biomarker Testing
Panelists discuss how in this discussion the top 3 key points were patient-centric care, enhanced multidisciplinary coordination, and increased access and equity. In the next 3 to 5 years there will be more decentralized testing, potentially more practices participating in genomic profiling, the cost of testing will go down and the turnaround time will be shorter.
Jonathan Lee, MD, MSc
Jonathan Lee, MD, MSc, is a chief Hematology/Oncology Fellow at Weill Cornell Medicine.
Latest:
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.
Amir Fathi, MD
Amir Fathi, MD, is program director of the Center for Leukemia at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School
Latest:
Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML
Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.
UAMS Winthrop P. Rockefeller Cancer Institute
Latest:
Pebbles Fagan, Ph.D., MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer Institute
Pebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.